Neuburgh Advisers LLC lessened its stake in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 12.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,512 shares of the company’s stock after selling 368 shares during the quarter. Neuburgh Advisers LLC’s holdings in Global Blood Therapeutics were worth $132,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC purchased a new position in Global Blood Therapeutics during the 2nd quarter valued at about $27,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Global Blood Therapeutics by 17.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,265 shares of the company’s stock valued at $172,000 after buying an additional 482 shares in the last quarter. LPL Financial LLC purchased a new position in Global Blood Therapeutics during the 2nd quarter valued at about $219,000. Shell Asset Management Co. purchased a new position in shares of Global Blood Therapeutics during the first quarter worth about $250,000. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Global Blood Therapeutics during the first quarter worth about $257,000. 97.99% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently commented on GBT shares. Morgan Stanley set a $60.00 price objective on Global Blood Therapeutics and gave the stock a “hold” rating in a report on Friday, August 9th. Cowen set a $83.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Thursday, September 5th. Goldman Sachs Group reissued a “neutral” rating and set a $75.00 price objective on shares of Global Blood Therapeutics in a report on Wednesday, May 29th. Wedbush reissued a “buy” rating and set a $120.00 price objective on shares of Global Blood Therapeutics in a report on Thursday. Finally, HC Wainwright set a $150.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $89.75.
Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Wednesday, August 7th. The company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.05). During the same period in the prior year, the company posted ($0.78) earnings per share. Research analysts forecast that Global Blood Therapeutics Inc will post -3.98 earnings per share for the current year.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Recommended Story: Municipal Bonds
Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.